Amyris (AMRS) Receives a Buy from H.C. Wainwright

By Carrie Williams

H.C. Wainwright analyst Amit Dayal maintained a Buy rating on Amyris (AMRSResearch Report) today and set a price target of $11. The company’s shares opened today at $3.85, close to its 52-week low of $2.92.

Dayal observed:

“We believe the company is capitalizing on its relationship with Xinfu / Yifan to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this high-margin revenue stream while continuing to benefit from future royalty payments.”

According to TipRanks.com, Dayal is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -18.3% and a 23.4% success rate. Dayal covers the Industrial Goods sector, focusing on stocks such as Ballard Power Systems, Capstone Turbine Corp, and Orion Energy Systems.

Amyris has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.29 and a one-year low of $2.92. Currently, Amyris has an average volume of 1.36M.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amyris, Inc. is an industrial biotechnology company, which engages in the provision of bioscience solutions. It focuses on the research, development, manufacture, and sale of fuels and farnesene-derived products. Its products include cosmetics, flavors and fragrances, performance materials, diesel, jet fuel, and lubricants. The company was founded by Jack D.